Dendritic cell-based vaccines

Another recent study supports the use of the dendritic cell-based vaccine as a therapeutic strategy to target both CD4 and CD8 T cells to HER-2 (Chen et al., 2001). To minimize the possibility of deleterious effects, the transforming activity of the HER-2 molecule can be inactivated by a single amino acid substitution (lysine to alanine), unlike other studies in which the entire intracellular domain was removed. 

In July 2007, a US biotech firm, Northwest Biotherapeutics, received approval form the Swiss Institute of Public Health to market to selected centers in Switzerland the first brain cancer vaccine, DCVax-Brain , an autologous patient-specific dendritic cell based vaccine. 

Zhang S, Wang Q, Miao B (2007) Review dendritic cell-based vaccine in the treatment of patients with advanced melanoma. Cancer Biother Radiopharm 22 501-507. 

Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, SchueUer G, Zontsich T, Benkoe T, Radelbauer K, Brostjan C, Jakesz R, Gnant M. Dendritic cell-based vaccination in solid cancer. J Clin Oncol 2003 21 135-142. 

Reinhard G, Marten A, Kiske SM, Feil F, Bieber T, Schmidt-Wolf IG. Generation of dendritic cell-based vaccines for cancer therapy. Br J Cancer 2002 86 1529-1533. 

Barratt-Boyes SM, Zimmer MI, Harshyne LA et al. Maturation and trafficking of monocyte-derived dendritic cells in monkeys implications for dendritic cell-based vaccines. J Immunol 2000 164 2487-2495. 

Tillman BW, Hayes TL, DeGruijl TD, Douglas JT, Curiel DT. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res 2000 60 5456-5463. 

Morisaki, T., K. Matsumoto, H. Onishi, H. Kuroki, E. Baba, A. Tasaki, M. Kubo, M. Nakamura, S. Inaba, K. Yamaguchi, M. Tanaka, and M. Katano (2003) Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients rationale, current progress, and perspectives. Hum Cell 16 175-182. 

Tatsumi T, Takehara T, Kanto T, Miyagi T, Kuzushita N, Sugimoto Y, Jinushi M, Kasahara A, Sasaki Y, Hori M, Hayashi N. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. Cancer Res 2001 61 7563-7567. 

Dohnal AM et al. Comparative evaluation of techniques for the manufacturing of dendritic cell-based cancer vaccines. J Cell Mol Med2008 E-pub. 

Chiappori, A. A., Soliman, H., Janssen, W. E., Antonia, S. J., and Gabrilovich, D. 1. 2010. lngn-225 A dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer Observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Jher, 10, 983-991. 

Elamanchili P, Diwan M, Cao M et al (2004) Characterization of poly(D, L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 22 2406—2412... 

Andre, F., Chaput, N., Schartz, N.E., Flament, C., Aubert, N., Bernard, J., Lemonnier, F., Raposo, G., Escudier, B., Flsu, D.Fl., Tursz, T., Amigorena, S., Angevin, E. and Zitvogel, L. (2004) Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class 1/peptide complexes to dendritic cells. J. Immunol. 172, 2126-2136. 

Kwon, Y.J., James, E., Shastri, N., Frechet, J.M. In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles. Proc. Natl. Acad. Sci. U. S. A. 102, 18264-18268 (2005)... 

---